PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This international, multicenter, randomized, double-blind phase III study intends to recruit 680 patients who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy) with postoperative pathological stage II or III (AJCC Cancer Staging Manual, 8th Edition) gastric or EGJ adenocarcinoma to evaluate the efficacy and safety of JS001 combined with postoperative adjuvant chemotherapy versus placebo combined with postoperative adjuvant chemotherapy.
Epistemonikos ID: 89c3403c3fa2376e0df04fc8f1cbf81bfc092aeb
First added on: May 09, 2024